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heart disease (prior myocardial infarction, 22.9% vs 44.2%, p<0.001), and more history
of hypertension (79.2% vs 55.1%, p<0.001). Slightly higher resting heart rates and blood
pressures were also observed in Blacks. While the reported HF etiology was predomi-
nantly hypertensive in Blacks and ischemic in Whites, the proportion of patients with pre-
served left ventricular function did not differ between the two groups, as 16.5% of Whites
and 16.7% of Blacks had left ventricular ejection fractions >40% (p=0.93). Physician
assessment of carvedilol titration demonstrated excellent tolerability in both groups, with
no problem or mildly difficult assessments recorded for 86.2% of Black patients vs 81.8%
of White patients, p=0.02. There was no difference in distribution of carvedilol dose by
race, with most patients achieving a dose of at least 6.25 mg bid. Compared to the 12
months prior to carvedilol initiation, hospitalization rates for all-causes, cardiovascular
reasons other than HF, and HF were reduced in both groups during carvedilol treatment.
The incidence of death per 1,000 person-years was similar in Blacks (71.0) and Whites
(73.6), and the hazard ratio was 1.01 (95% CI 0.68 to 1.49; p=0.96).
Conclusions: In the community setting of COHERE, carvedilol was well tolerated in
Blacks who, despite different baseline characteristics and risk factors for HF, also demon-
strated safety and efficacy comparable to that seen in White patients.
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Background: Increased morbidity and mortality in heart failure (HF) patients has been
related to risk factors derived from populations in clinical trials, at hospital discharge, or in
localized geographic/socioeconomic strata, and were identified before wide use of beta-
blockers for HF.
Methods: The Coreg Heart Failure Registry (COHERE) observed 4,280 unselected HF
patients during 1-yr follow-up after initiating carvedilol in a community setting. Patients
entered the registry regardless of ejection fraction (EF). Significant risk factors for the
composite of death, hospitalization for HF and hospitalization for cardiovascular (CV)
reasons other than HF were identified by age-, sex-, and race-adjusted analyses. Inde-
pendent risk factors were identified from a multivariable analysis adjusted for all factors
simultaneously.
Results: Over this period 7% of patients died, 11% were hospitalized for HF, 12% were
hospitalized for other CV reasons, and 27% had any of these events. Key findings of the
multivariate analysis are shown in the table. 
Although EF and blood pressure were significant predictors when adjusted for age, sex,
and race, the relationship did not persist when simultaneously adjusted for other co-vari-
ables.
Conclusions: Simple historical information identifies community HF patients at
increased risk for death or hospitalization in the year after initiating carvedilol. In this pop-
ulation not selected by EF, these historical factors appear to better predict risk than did
EF.
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Introduction: The impact of combination "evidence-based" therapy (ASA, beta-blockers,
ace inhibitors, and statin use) on long-term survival of patients undergoing percutaneous
coronary intervention (PCI) is uncertain.
Hypothesis: We hypothesized that post-PCI patients with higher rates of use of evi-
dence-based therapy would have lower mortality rates.
Methods: We collected clinical and angiographic data on consecutive PCIs from July
1997 to October 2001. An additive evidence-based therapy score (0-4) was calculated by
applying 1 point each to hospital discharge on ASA, beta-blockers, ace inhibitors and
statins. Follow-up long-term survival was obtained by telephone contact and/or searching
the Social Security Death Index. Using a Cox proportional hazards model, we assessed
the impact of the score on survival after adjusting for age, sex, cardiac risk factors (e.g.,
diabetes(DM), hypertension, congestive heart failure, ejection fraction, extent of coronary
disease, renal insufficiency, hx of bypass surgery/PCI/acute myocardial infarction(MI),
clinical priority and procedural factors (e.g., stent, gIIb/IIIa use).
Results: 2311 patients underwent 3231 PCIs with a mean-follow-up of 344 +/- 225 days.
Mean age was 63 +/- 12 years; 752 (33%) were women, 609 (26%) had DM, 487 (19%)
had recent MI. Most (78%) received stents. 211 (9%) patients were discharged on 0-1
evidence-based therapies (i.e., score of 0-1) and 570 (25%) were discharged on all 4 evi-
dence-based therapies. After multivariate adjustment, the evidence-based therapy score
remained an independent predictor of improved survival (HR per 1 unit increase in evi-
dence-based therapy score, 0.78; 95% ci, 0.66-0.92; p=0.003). Other significant factors
included: advanced age, congestive heart failure, ejection fraction, left main disease,
multivessel PCI, renal insufficiency, and post-PCI QWMI.
Conclusion: The use of combination evidence-based therapy as assessed by an addi-
tive score is independently associated with improved survival after PCI. Evidence-based
therapy use should be strongly encouraged and implemented in these patients.
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Background: We have several prognosis models for heart surgery (HS). However, these
scores were based on preoperative variables, our model have used both, preoperative
and first postoperative day (FPOD) . Objectives: To create a predictive score of in-hospi-
tal mortality in patients (pts) undergoing HS and admitted to a public and private surgical
intensive care unit (SICU), analyzing pre-, perioperative and FPOD variables. Case
series and methods: Classical cohort of data (1,458 pts) consecutively collected from
June 2000 to February 2003. All 46 variables were previously defined according to the
major prognostic index found in the literature. The statistical analysis comprised: univari-
ate analysis with the chi-square test, Student t test, Mann-Whitney and Pearson tests, fol-
lowed by logistic regression and stepwise (likelihood ratio), with the linear trend test and
ROC curve. Results: The score , shown in the attached table, provides the following risk
prediction: 0 to 4 – low risk; 5 to 9 – medium; and 10 to 14 – high. The results had signif-
icance (p<0.0001) and linear trend (p<0,0001). The area under the ROC curve was 0.84.
Conclusions: The score shows the strength of the variables on the FPOD, such as worse
PO2/ FiO2 < 100, epinephrine > 0,1 or norepinephrine > 0,1, and mechanical ventilation
duration > 12 h, probably related to perioperative factors, such as type of anesthesia,
host response, hemodynamic profile, use or nonuse of corticosteroids.
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Background: The development of pulmonary hypertension (PH) has been reported in
most hemolytic anemias and preliminary reports have suggested its prognostic value in
sickle cell disease (SSD). We, therefore, assessed the predictive values of transthoracic
Variable Odds 
Ratio
95% Confidence 
Limits
P
NYHA class (IV vs I) 3.56 2.23 - 5.68 <0.001
NYHA class (III vs I) 2.85 2.08 - 3.91 <0.001
HF Hospitalization prior yr 1.92 1.63 - 2.25 <0.001
NYHA class (II vs I) 1.66 1.22 - 2.26 <0.001
History of angina 1.38 1.17 - 1.63 <0.001
HF duration (> 2yr vs < 6 mos) 1.28 1.06 - 1.54 0.009
History of diabetes 1.22 1.04 - 1.43 0.013
History of acute MI 1.20 1.01 - 1.43 0.039
MD (non-cardiologist vs cardiologist) 1.12 0.94 - 1.33 0.216
Sex (males vs females) 1.05 0.89 - 1.23 0.555
Age ( per 1 yr increase) 1.01 1.00 - 1.01 0.171
Race (Black vs Caucasian) 1.00 0.78 - 1.28 0.992
MD (yrs since graduation 19-24 vs <13 yr) 0.82 0.68 - 1.00 0.055
MD (yrs since graduation 13-18 vs <13 yr) 0.76 0.62 - 0.94 0.011
Insurance (commercial vs Medicare/Medicaid) 0.76 0.60 - 0.95 0.017
MD (yrs since graduation >24 vs <13 yr) 0.71 0.58 - 0.87 <0.001
HF cause (Idiopathic vs CAD) 0.71 0.55 - 0.91 0.007
HF cause (HTN vs CAD) 0.69 0.53 - 0.89 0.004
CAD = coronary artery disease; HTN = hypertension
95% CI for OR
Characteristics OR Lower Upper Score
Age 64 to 74years 2,05 1,16 3,63 +1
Age >75 years 4.79 2,60 8,83 +2
Left atrium>45mm 2,58 1,53 4,37 +1
Creatinine>2mg/dl 4,84 1,87 12,48 +2
Extracorporeal circulation>180min 4,93 1,99 12,18 +2
Worse FPOD PO2/FiO2 < 100 9,47 3,18 28,23 +3
FPOD Epinephrine > 0.1 or Nor > 0.1 mcg/kg/min 6,78 3,99 11,53 +3
FPOD duration of mechanical ventilation > 12 h 2,24 1,34 3,72 +1
